Clinical Trials Logo

Clinical Trial Summary

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

NCT number NCT04280718
Study type Interventional
Source argenx
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 18, 2020
Completion date March 1, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT06040567 - Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
Recruiting NCT05492604 - Comparison of FEETME® Soles and GAITRITE® Walkway for the Evaluation of Gait Disorders in CIDP. N/A
Not yet recruiting NCT03166527 - Panzyga in CIDP Administered at Different Infusion Rates Phase 3
Completed NCT02027701 - Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Completed NCT04281472 - A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Phase 2
No longer available NCT05014724 - CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)